Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

1.21
+0.0000
Volume:302.04K
Turnover:365.96K
Market Cap:95.08M
PE:-1.89
High:1.23
Open:1.20
Low:1.18
Close:1.21
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Yesterday

The Smartest Growth Stock to Buy With $1,000 Right Now

Motley Fool
·
19 Mar

Tom's of Maine Introduces Whiten+ Toothpaste: Natural, Effective Whitening

PR Newswire
·
05 Mar

NASA May Cancel Boeing's Big $82 Billion Space Opportunity

Motley Fool
·
23 Feb

Blue Origin Prepares for Layoffs. Here's What Space Stock Investors Need to Know

Motley Fool
·
22 Feb

Boeing to Cut 400 Jobs on NASA's SLS Moon Rocket Program

MT Newswires Live
·
10 Feb

Largest borrow rate increases among liquid names

TIPRANKS
·
03 Feb

Sellas $25M registered direct offering priced at $1.27 per share and warrant

TIPRANKS
·
29 Jan

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
29 Jan

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
29 Jan

SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

MT Newswires Live
·
24 Jan

Sellas Life Sciences announces IDMC completed interim analysis of REGAL trial

TIPRANKS
·
23 Jan

Sellas Life Sciences Group Inc: 80% of Randomly Selected Regal Gps Patients Showed a Specific T-Cell Immune Response

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Group: Idmc Has Recommended That Trial Continue Without Modifications

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia

THOMSON REUTERS
·
23 Jan

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire
·
23 Jan